SUMMARY
Parkinson’s Disease (PD) is the second most common and fastest-growing neurological disorder. Polygenic Risk Scores (PRS) using hundreds to thousands of PD-associated variants support polygenic heritability. Here, for the first time, we apply a genome-wide polygenic risk score approach using 6.2 million variants to compute a PD genome-wide polygenic risk score (PD-GPRS) via the LDPred algorithm. PD-GPRS validation and testing used Accelerating Medicines Partnership – Parkinson’s Disease (AMP-PD) and FinnGen Consortia genomic data from 1,654 PD Cases and 79,123 Controls. PD odds for the top 8%, 2.5%, and 1% of PD-GPRS were three-, four-, and seven times greater compared with lower percentiles, respectively (p<1e-10). PD age of onset and MDS-UPDRS motor scores also differed by PD-GPRS decile. Enrichment for phagosome related, dopamine signaling, immune related, and neuronal signaling pathways was found for genes nearest high PD-GPRS variants identified by MAF analysis. PD-GPRS offers a promising screening tool to identify high-risk individuals for preventive lifestyle or new drug therapy trials.
In Brief In Han and Teeple et al., Parkinson’s Disease inherited risk is quantified by a genome-wide polygenic risk score (PD-GPRS) approach using 6.2 million variants and data from 80,777 individuals. For the top 2.5% and 1% of PD-GPRS, individuals had five- and seven-fold greater odds of PD, respectively. PD-GPRS was found to be associated with overall PD risk, earlier age of onset, and MDS-UPDRS motor scores. Genes nearest to variants observed at higher frequencies among high-GPRS individuals are enriched for PD-implicated pathways.
HIGHLIGHTS
- Parkinson’s Disease genome-wide polygenic risk score (PD-GPRS) calculated from 6.2 million variants identifies individuals with inherited clinically significant increased neurodegeneration risk.
- Top percentile PD-GPRS individuals were found to have up to seven-fold greater odds of PD and earlier age at PD diagnosis.
- PD-GPRS scores correlated with all-subjects cohort mean MDS-UPDRS motor scores.
- Pathway analysis of genes adjacent to frequently occurring variants in the high PD-GPRS population identified polygenic risk contributions for variations in PD-implicated pathways including dopamine signaling, immune responses, and autophagy pathways.
Competing Interest Statement
Y.H., E.T., S.S, M.S., C.Z., D.L., C.W., F.F, K.W.K., S.P.S., S.L.M., D.R., D.K. are employees of Sanofi.
Funding Statement
The work is fully supported by Sanofi, please see the acknowledgement section for the details.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data used for this analysis comes from AMPD PD and FinnGen Consortia. Consortia ethics approval information is included below and in the manuscript text. All analyses were performed in compliance with consortia data use agreements and in secure computing environments. Prior to submission, the submitted manuscript was reviewed by AMP-PD and FinnGen to further ensure ethical compliance and written confirmation of approval for publication has been obtained from both AMP-PD and FinnGen. FinnGen: FinnGen is a public-private partnership between the Finnish National Institute for Health and Welfare, universities, biobanks, and a number of pharmaceutical companies which was launched in 2017 with the aim of collecting health and genomic sequencing data from 500,000 individuals for use in analysis to identify new diagnostic methods and therapies [22]. Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen project is approved by Finnish Institute for Health and Welfare (THL), approval number THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019), Digital and population data service agency VRK43431/2017-3, VRK/6909/2018-3, the Social Insurance Institution (KELA) KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019 and Statistics Finland TK-53-1041-17. AMP-PD: AMP-PD is a public-private partnership between the United States National Institutes of Health, non-profit organizations, and pharmaceutical and life sciences companies which aims to identify and validate new, impactful biological targets for PD therapeutics. Using the Terra platform for data access and analysis, AMP-PD makes available unified data from a number of published PD cohort studies: the Michael J. Fox Foundation (MJFF) and National Institutes of Neurological Disorders and Stroke (NINDS) BioFIND study, Harvard Biomarkers Study (HBS), the NINDS Parkinsons Disease Biomarkers Program (PDBP), and MJFF Parkinsons Progression Marker Initiative (PPMI)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Analysis code will be made available as supplemental files at the time of publication. FinnGen data is restricted and requires authorization for access: https://www.finngen.fi/en/about. Unified Amp-PD Cohorts data is restricted and requires authorization for access: https://amp-pd.org/ Information and access to the Terra computing platform can be found at https://terra.bio/. Terra is developed by the Broad Institute of MIT and Harvard in collaboration with Verily Life Sciences. The Terra system was used for access to AMP-PD data and for computing PD-GPRS scores using LDPred algorithm. LDpred is a Python-based software package which adjusts GWAS summary statistics for the effects of linkage disequilibrium (LD). The method reference is Vilhjalmsson et al. (AJHG 2015) [http://www.cell.com/ajhg/abstract/S0002-9297(15)00365-1]. LDPred code is available at https://github.com/bvilhjal/ldpred. Parkinsons Disease Genome-Wide Association Study (GWAS) summary statistics from Nalls et al. used for PD-GPRS calculation using LDPRed are available from a supplementary table to the publication[16]. Complete summary statistics table: https://www.biorxiv.org/content/10.1101/388165v3.full.pdf, link to data table file is found under heading DATA ACCESS. Genome reference panel source is 1000 Genomes Project phase 3: https://www.internationalgenome.org/data/.
